Cue Biopharma, Inc. (CUE)
28.18
+0.02
(+0.07%)
USD |
NASDAQ |
Aug 28, 16:00
28.18
0.00 (0.00%)
After-Hours: 18:01
Cue Biopharma Cash from Operations (Quarterly) : -29.00M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -29.00M |
| March 31, 2026 | -10.94M |
| December 31, 2025 | -1.076M |
| September 30, 2025 | -9.024M |
| June 30, 2025 | -3.415M |
| March 31, 2025 | -8.172M |
| December 31, 2024 | -9.028M |
| September 30, 2024 | -7.527M |
| June 30, 2024 | -9.99M |
| March 31, 2024 | -9.784M |
| December 31, 2023 | -10.96M |
| September 30, 2023 | -7.799M |
| June 30, 2023 | -10.37M |
| March 31, 2023 | -10.83M |
| December 31, 2022 | -10.51M |
| September 30, 2022 | -6.871M |
| June 30, 2022 | -12.85M |
| March 31, 2022 | -11.57M |
| Date | Value |
|---|---|
| December 31, 2021 | -10.65M |
| September 30, 2021 | -6.627M |
| June 30, 2021 | -9.77M |
| March 31, 2021 | -11.80M |
| December 31, 2020 | -6.999M |
| September 30, 2020 | -7.687M |
| June 30, 2020 | -6.864M |
| March 31, 2020 | -10.94M |
| December 31, 2019 | -6.438M |
| September 30, 2019 | -9.208M |
| June 30, 2019 | -6.676M |
| March 31, 2019 | -8.475M |
| December 31, 2018 | -3.898M |
| September 30, 2018 | -6.298M |
| June 30, 2018 | -6.456M |
| March 31, 2018 | -9.759M |
| December 31, 2017 | -1.896M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 58.28M |
| Fortress Biotech, Inc. | -59.28M |
| Equillium, Inc. | -4.107M |
| Legend Biotech Corp. | -20.87M |
| Nurix Therapeutics, Inc. | -96.57M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | 30.02M |
| Free Cash Flow | -50.17M |
| Free Cash Flow Per Share (Quarterly) | -4.574 |
| Free Cash Flow to Equity (Quarterly) | -34.37M |
| Free Cash Flow to Firm (Quarterly) | -29.00M |
| Free Cash Flow Yield | -39.14% |